PCI-27483 is a potent and selective small-molecule inhibitor of activated factor VII (factor VIIa). FVII, a serine protease, becomes activated (FVIIa) upon binding with TF forming the FVIIa/TF complex, which induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2). Upon subcutaneous administration, PCI-27483 selectively inhibits factor FVIIa in the VIIa/TF complex, which may prevent PAR-2 activation and PAR2-mediated signal transduction pathways, thereby inhibiting tumor cell proliferation, angiogenesis, and metastasis of TF-overexpressing tumor cells. In addition, this agent inhibits both the extrinsic and intrinsic coagulation cascades, preventing blood clot formation. TF, a blood protein overexpressed on the cell surface of a variety of tumor cell types, may correlate with poor prognosis; PAR-2 (also known as thrombin receptor-like 1) is a G protein-coupled receptor (GPCR) and a protease-activated receptor.

KEYWORDS: PCI-27483 | Supplier | FVIIa/tissue factor inhibitor | PCI27483 | PCI 27483 | CT-PCI274 | CAS [871266-63-6] | Non Selective (Serine peptide bonds) | FVIIa | Inhibitor | Enzymes